NASDAQ · Biotechnology · USD
Enveric Biosciences, Inc. (ENVB) Stock Analysis
Enveric Biosciences, Inc. (ENVB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ENVB Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.47
- Previous Close
- $1.44
- Day's Range
- 1.43–1.59
- 52-Week Range
- 1.17–13.25
- Volume
- 82.81K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.18
Valuation
- Market Cap
- $6.76M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −13.01
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$8.77M
- Shares Outstanding
- 4.48M
- 1-Year Return
- −81.47%
Dividend and dates
- Avg Volume
- 96.11K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ENVB closed at $1.51, −81.47% over 1 year.
Enveric Biosciences, Inc. (ENVB) has a market capitalization of $6.76M.
In fiscal 2025, ENVB reported revenue of $0.00.
ENVB Stock Return by Calendar Year
Enveric Biosciences, Inc. (ENVB) return since Jan 2025: what $10,000 became
- 1 year
- $10,000 $1,853
- −81.47%
- Since Jan 2025
- $10,000 $14
- −99.86%
If you had invested $10,000 in Enveric Biosciences, Inc. (ENVB) at the close on January 10, 2025, the earliest close on record here, it would have been worth $14 at the close on October 21, 2026: −99.86% in total, −97.53% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −58.40% |
| 2025 | −99.67% |
As of October 21, 2026.
ENVB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$8.77M | — |
| 2024 | $0.00 | −$9.57M | — |
| 2023 | $0.00 | −$17.31M | — |
| 2022 | $0.00 | −$18.50M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$8.77M | −$8.77M | — |
| 2024 | $0.00 | — | −$9.63M | −$9.57M | — |
| 2023 | $0.00 | — | −$18.30M | −$17.31M | — |
| 2022 | $0.00 | — | −$19.96M | −$18.50M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
BenzingaEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
YahooEnveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates
BenzingaEnveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
YahooEnveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
BenzingaEnveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B